Literature DB >> 8320743

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

M D Brundage1, J L Pater, B Zee.   

Abstract

BACKGROUND: The toxicity of a given cancer therapy is an important end point in clinical trials examining the potential costs and benefits of that therapy. Treatment-related toxicity is conventionally measured with one of several toxicity criteria grading scales, even though the reliability and validity of these scales have not been established.
PURPOSE: We determined the reliability of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) expanded toxicity scale and the World Health Organization (WHO) standard toxicity scale by use of a clinical simulation of actual patients.
METHODS: Seven experienced data managers each interviewed 12 simulated patients and scored their respective acute toxic effects. Inter-rater agreement (agreement between multiple raters of the same case) was calculated using the kappa (kappa) statistic across all seven randomly assigned raters for each of 18 toxicity categories (13 NCIC-CTG and five WHO categories). Intra-rater agreement (agreement within the same rater on one case rated on separate occasions) was calculated using kappa over repeated cases (where raters were blinded to the repeated nature of the subjects). Proportions of agreement (estimate of the probability of two randomly selected raters assigning the same toxicity grade to a given case) were also calculated for inter-rater agreement. Since minor lack of agreement might have adversely affected these statistics of agreement, both kappa and proportion of agreement analyses were repeated for the following condensed grading categories: none (0) versus low-grade (1 or 2) versus high-grade (3 or 4) toxicity present.
RESULTS: Modest levels of inter-rater reliability were demonstrated in this study with kappa values that ranged from 0.50 to 1.00 in laboratory-based categories and from -0.04 to 0.82 for clinically based categories. Proportions of agreement for clinical categories ranged from 0.52 to 0.98. Condensing the toxicity grades improved statistics of agreement, but substantial lack of agreement remained (kappa range, -0.04-0.82; proportions of agreement range, 0.67-0.98).
CONCLUSIONS: Experienced data managers, when interviewing patients, draw varying conclusions regarding toxic effects experienced by such patients. Neither the NCIC-CTG expanded toxicity scale nor the WHO standard toxicity scale demonstrated a clear superiority in reliability, although the breadth of toxic effects recorded differed.

Entities:  

Mesh:

Year:  1993        PMID: 8320743     DOI: 10.1093/jnci/85.14.1138

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  18 in total

1.  An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

Authors:  H Hirte; D Stewart; R Goel; E Chouinard; S Huan; S Stafford; B Waterfield; S Matthews; C Lathia; B Schwartz; V Agarwal; R Humphrey; And L Seymour
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

2.  Chemotherapy-induced neuropathy.

Authors:  Guido Cavaletti; Paola Alberti; Barbara Frigeni; Marialuisa Piatti; Emanuela Susani
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

3.  Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists.

Authors:  Minh-Phuong Huynh-Le; Zhe Zhang; Phuoc T Tran; Theodore L DeWeese; Daniel Y Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-13       Impact factor: 7.038

4.  Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4).

Authors:  Michelle A Neben-Wittich; Pamela J Atherton; David J Schwartz; Jeff A Sloan; Patricia C Griffin; Richard L Deming; Jon C Anders; Charles L Loprinzi; Kelli N Burger; James A Martenson; Robert C Miller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

5.  An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.

Authors:  R Goel; E Chouinard; D J Stewart; S Huan; H Hirte; S Stafford; B Waterfield; J Roach; C Lathia; V Agarwal; R Humphrey; W Walsh; S Matthews; L Seymour
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

6.  Health-related quality of life and cancer clinical trials.

Authors:  David Osoba
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

7.  Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial.

Authors:  A Chatterjee; M G Swain; S S Lee; V G Bain; K Peltekian; K Croitoru; P C Adams; K Kaita; J Teitel; E J Heathcote
Journal:  Can J Gastroenterol       Date:  2007-02       Impact factor: 3.522

Review 8.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

9.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Authors:  Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2009-11-17       Impact factor: 13.506

10.  Advantages and Adversities of the Weighted Toxicity Score.

Authors:  Ulka Vaishampayan
Journal:  Clin Cancer Res       Date:  2018-07-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.